ARDX
Ardelyx, Inc.
NASDAQ · USHealthcareBiotechnology
$5.09-2.12%
Price as of Jul 20, 2026
ARDX growth
Ardelyx, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +18.2%
- EBITDA
- +9.6%
- EBIT
- +5.6%
- EPS
- -5.0%
- Free cash flow
- +23.0%
- Operating cash flow
- +23.7%
Forward estimates
- Revenue
- +46.1%
- EBITDA
- —
- EPS
- +161.8%
Three-year CAGR
- Revenue
- +98.4%
- EBITDA
- -74.6%
- EBIT
- -46.6%
- Net income
- -57.4%
- EPS
- -52.9%
- Free cash flow
- +4.0%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.